PFE250502C29000
- 0.01
- 0.000.00%
Pfizer Newsroom
Pfizer Sticks to 2025 Profit View as It Shrugs off Plunging Paxlovid Sales for COVID
UBS Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $24
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE) and Nautilus Biotechnolgy (NAUT)
Health Care Climbs Amid Mixed Earnings - Health Care Roundup
Pfizer Options Spot-On: On April 29th, 300.26K Contracts Were Traded, With 3.35 Million Open Interest
Earnings Call Summary | Pfizer(PFE.US) Q1 2025 Earnings Conference
Pfizer Targets $7.7B in Operational Efficiency Savings by 2027, Highlights Strategic R&D Shifts
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
Pfizer Cuts Spending on Weaker Sales
Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com
Sector Update: Health Care
Pfizer CEO Says Tariff Uncertainty Is Deterring Further U.S. Investment in Manufacturing, R&D
Pfizer Shares Are Trading Higher Following a Q1 EPS Beat. The Company Reaffirmed Guidance but Said It Is Trending Towards the Upper End of Its 2025 Adjusted Diluted EPS Guidance Range.
Express News | Pfizer Shares Are Trading Higher Following a Q1 EPS Beat. The Company Reaffirmed Guidance but Said It Is Trending Towards the Upper End of Its 2025 Adjusted Diluted EPS Guidance Range
Stocks Making the Biggest Moves Midday: Spotify, General Motors, Royal Caribbean, Pfizer and More
Dow Boosted by Honeywell, Sherwin-Williams While S&P and Nasdaq Seesaw
Express News | Live On CNBC Josh Brown Announces Sold Some Pfizer